Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss
Lead sponsor
Asset
Tirzepatide
Subcutaneous · GLP-1 / GIP dual
Listed sites
1
Recruiting sites
1
Estimated enrollment
42
Study population
Bariatric Surgery, Obesity / overweight
Eligibility highlights
•BMI ≥35
Primary endpoint
•Weight Loss
Registered trial locations
Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Who this study enrolls
Who can enroll
Inclusion criteria
Exclusion criteria
Endpoints (12)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Coverage by outcome category
Weight & body composition
2 endpointsWeight Loss
Time frame:12 months after surgery
descriptive, improvement
Weight Loss
Time frame:18 months after surgery
descriptive, improvement
Glycemic / diabetes
2 endpointsType 2 Diabetes
Time frame:12 months after surgery
HbA1c, change
change from baseline, improvement
LOINC 4548-4
Type 2 Diabetes
Time frame:18 months after surgery
HbA1c, change
change from baseline, improvement
LOINC 4548-4
Cardiometabolic biomarkers
4 endpointsHigh Blood Pressure
Time frame:12 months after surgery
categorical status, improvement
High Blood Pressure
Time frame:18 months after surgery
categorical status, improvement
High Cholesterol
Time frame:12 months after surgery
event count, improvement
High Cholesterol
Time frame:18 months after surgery
event count, improvement
Safety / tolerability / PK
2 endpointsComplications/Side Effects
Time frame:12 months after surgery
descriptive
Complications/Side Effects
Time frame:18 months after surgery
descriptive
Other clinical outcomes
2 endpointsSleep Apnea
Time frame:12 months after surgery
categorical status, improvement
Sleep Apnea
Time frame:18 months after surgery
categorical status, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.